Infinitopes, a clinical-stage cancer vaccine biotechnology company, has secured an additional £11 million in the second close of its seed financing round, bringing the total raised to £26 million. The investment was co-led by Octopus Ventures and new investor Amplify Bio, with further participation from new investor Macmillan Cancer Support alongside existing investors Cancer Research Horizons and Manta Ray Ventures.
The funding coincides with the launch of Infinitopes’ first-in-human, double-blind, randomised, placebo-controlled clinical trial of ITOP1, its leading precision therapeutic vaccine aimed at preventing recurrence in oesophageal cancer, an area where clinical need remains largely unmet.
The Phase I/IIa VISTA trial will be conducted across multiple UK NHS university cancer centres. The trial is designed to enable proof-of-concept evaluation of Infinitopes’ precision targeted, off-the-shelf vaccine platform to prevent recurrence after surgical resection.
Infinitopes plans to share early findings from the trial at major conferences later this year.
I'm honoured to welcome leading US West Coast biofund Amplify Bio and ecosystem champions for better patient care, Macmillan, onto our cap table. This new funding unlocks our potentially groundbreaking Phase I/IIa trial, enabling proof-of-concept evaluation of Infinitopes' AI/ML-precision targeted, off-the-shelf vaccine platform to prevent recurrence after surgical resection. We aim to lead the development of innovative medicines that bring hope to patients suffering from cancers with unmet medical needs. We anticipate sharing our early findings at major conferences later this year.
Jonathan Kwok, Founder & CEO
Recent clinical evidence has made it abundantly clear that the time for cancer vaccines is now. After years of searching, Infinitopes has clearly distinguished itself as the company positioned to drive this progress forward. The combination of rigorous AI-powered immunomics profiling, a highly scalable off-the-shelf vector, and a defined clinical strategy is exactly what this field needs. Infinitopes has the potential to redefine immunotherapy and precision oncology in the years to come.
Partner at Amplify Bio
